Zepbound News

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen - CNBC

Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen CNBC

Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen - WSJ

Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen WSJ

FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland - Baltimore Sun

FDA cracks down on weight-loss drug alternatives as thousands sickened in Maryland Baltimore Sun

Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound - WSJ

Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound WSJNovo Nordisk downgraded by leading banks as CagriSema trial flops against Zepbound Yahoo FinanceNovo's CagriSema fails to match Lilly's Zepbound in key obesity trial FirstWord Pharma

Lilly adds multidose Zepbound pens to self-pay menu after FDA nod - Fierce Pharma

Lilly adds multidose Zepbound pens to self-pay menu after FDA nod Fierce Pharma

Tirzepatide Now Available in Multi-Dose KwikPen - Medscape

Tirzepatide Now Available in Multi-Dose KwikPen Medscape

Why Eli Lilly is suddenly pulling ahead in the GLP-1 weight-loss race - Fast Company

Why Eli Lilly is suddenly pulling ahead in the GLP-1 weight-loss race Fast Company

Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know - Good Morning America

Eli Lilly launches new weight-loss drug Zepbound KwikPen: What to know Good Morning America

Novo to cut Ozempic and Wegovy prices amid intense competition - The Detroit News

Novo to cut Ozempic and Wegovy prices amid intense competition The Detroit News

Novo’s CagriSema stumbles against Lilly’s Zepbound in Phase III showdown - The Pharma Letter

Novo’s CagriSema stumbles against Lilly’s Zepbound in Phase III showdown The Pharma Letter

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Eli Lilly and Company

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Eli Lilly and Company

Novo Nordisk’s next-gen obesity drug stumbles in comparison study - statnews.com

Novo Nordisk’s next-gen obesity drug stumbles in comparison study statnews.com

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity - HCPLive

Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity HCPLive

Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial - Clinical Trials Arena

Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial Clinical Trials Arena

Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test - BioSpace

Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test BioSpace

Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price - Fierce Biotech

Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price Fierce Biotech

Multi-Dose KwikPen Now Available for Zepbound Administration - Medical Professionals Reference

Multi-Dose KwikPen Now Available for Zepbound Administration Medical Professionals Reference

zepbound weight loss drug gets new, more convenient packaging - WFAA

zepbound weight loss drug gets new, more convenient packaging WFAA

Novo Nordisk slumps further on weight loss drugs in fight with Eli Lilly - Axios

Novo Nordisk slumps further on weight loss drugs in fight with Eli Lilly Axios

How Investors Are Reacting To Eli Lilly (LLY) Expanding Zepbound With A Monthly KwikPen Amid Rival Trial Setback - simplywall.st

How Investors Are Reacting To Eli Lilly (LLY) Expanding Zepbound With A Monthly KwikPen Amid Rival Trial Setback simplywall.st

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen - Yahoo Finance

Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen Yahoo Finance

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study - BioPharma Dive

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study BioPharma Dive

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight - Eli Lilly and Company

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight Eli Lilly and Company

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study - CNBC

Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study CNBC

FDA approves four-dose Zepbound KwikPen for weight loss - ConsumerAffairs

FDA approves four-dose Zepbound KwikPen for weight loss ConsumerAffairs

Diabetes Dialogue: Launch of the Zepbound KwikPen - HCPLive

Diabetes Dialogue: Launch of the Zepbound KwikPen HCPLive

Novo Nordisk eats Eli Lilly’s dust again - Morning Brew

Novo Nordisk eats Eli Lilly’s dust again Morning Brew

Novo's 'triple G' delivers near-20% weight loss in Chinese study - FirstWord Pharma

Novo's 'triple G' delivers near-20% weight loss in Chinese study FirstWord Pharma

Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin - Investor's Business Daily

Novo Nordisk Dives As Next-Gen Obesity Drug Lags Eli Lilly's Kingpin Investor's Business Daily

Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. - Reuters

Novo hoped its next obesity drug would close the gap. Instead, it may have widened Eli Lilly’s lead. Reuters

Novo downgraded at J.P. Morgan on CagriSema data (NVO:NYSE) - Seeking Alpha

Novo downgraded at J.P. Morgan on CagriSema data (NVO:NYSE) Seeking Alpha

Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly - Reuters

Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly Reuters

New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound - Scientific American

New GLP-1 weight-loss drugs are coming—and they’re stronger than Wegovy and Zepbound Scientific American

Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity 'silos' - Fierce Pharma

Lilly chalks up another trial win for Zepbound-Taltz combo in bid to break down psoriasis, obesity 'silos' Fierce Pharma